Replies to post #525777 on NorthWest Biotherapeutics Inc (NWBO)

[HyGro]

"The study’s primary endpoint is PFS, and the secondary endpoint is OS. PFS has not yet been evaluated for this publication and will be the subject of later analyses to allow for central, multi-factorial assessment by an expert panel, using criteria currently emerging as appropriate for immune therapy in this patient population"

"the final patient was enrolled in November of 2015." So when this interim report was released, NWBO had seem almost all of the PFS events and Dr. Liau still was supporting PFS as the primary endpoint because of the "expert panel, using criteria currently emerging as appropriate for immune therapy"

Guess once they analyzed the PFS data and DCVax-L failed to meet the endpoint, NWBO knew they were in trouble and hand to look at manipulating the protocol to get more positive results. That was even though the naive OS data was confounded by double dosing all the patients. Not going to pretty when the regulators see the history of this trial.

[sentiment_stocks]

And this article is ranked an impressive 111th of 302,452 tracked articles of a similar age…

This article is in the 99th percentile (ranked 111th) of the 302,452 tracked articles of a similar age in all journals and the 1st percentile (ranked 1st) of the 1 tracked articles of a similar age in Journal of Translational Medicine